Evidence map›Paper›PMID 27852146›Full record

ArticleXenobiotica; the fate of foreign compounds in biological systems2017

Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice.

Makiko Shimizu, Hiroshi Suemizu, Marina Mitsui, Norio Shibata, F Peter Guengerich, Hiroshi Yamazaki

Open access · greenAbstract read
In one paragraph

Article in Xenobiotica; the fate of foreign compounds in biological systems, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. AttenuatedFrontiers in immunology · 2020
    Article
  7. P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity.Drug metabolism and disposition: the biological fate of chemicals · 2018
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Makiko Shimizua Laboratory of Drug Metabolism and Pharmacokinetics , Showa Pharmaceutical University , Tokyo , Japan.ORCID http://orcid.org/0000-0002-3706-2454
Hiroshi Suemizub Central Institute for Experimental Animals , Kawasaki , Japan.
Marina Mitsuia Laboratory of Drug Metabolism and Pharmacokinetics , Showa Pharmaceutical University , Tokyo , Japan.
Norio Shibatac Graduate School of Engineering, Nagoya Institute of Technology , Nagoya , Japan , and.
F Peter Guengerichd Department of Biochemistry , Vanderbilt University School of Medicine , Nashville , TN , United States.
Hiroshi Yamazakia Laboratory of Drug Metabolism and Pharmacokinetics , Showa Pharmaceutical University , Tokyo , Japan.ORCID http://orcid.org/0000-0002-1068-4261
Showa Pharmaceutical University · JPCentral Institute for Experimental Animals · JPNagoya Institute of Technology · JPVanderbilt University · US

Funding

Metabolism of Carcinogens and Drugs by Human P450sR01GM118122 · NIGMS · VANDERBILT UNIVERSITY · PI GUENGERICH, F PETER · 2016 to 2023
$3.3M
NIGMS NIH HHS R01 GM118122
6 · The paper itself

Abstract

1. Pomalidomide has been shown to be potentially teratogenic in thalidomide-sensitive animal species such as rabbits. Screening for thalidomide analogs devoid of teratogenicity/toxicity - attributable to metabolites formed by cytochrome P450 enzymes - but having immunomodulatory properties is a strategic pathway towards development of new anticancer drugs. 2. In this study, plasma concentrations of pomalidomide, its primary 5-hydroxylated metabolite, and its glucuronide conjugate(s) were investigated in control and humanized-liver mice. Following oral administration of pomalidomide (100 mg/kg), plasma concentrations of 7-hydroxypomalidomide and 5-hydroxypomalidomide glucuronide were slightly higher in humanized-liver mice than in control mice. 3. Simulations of human plasma concentrations of pomalidomide were achieved with simplified physiologically-based pharmacokinetic models in both groups of mice in accordance with reported pomalidomide concentrations after low dose administration in humans. 4. The results indicate that pharmacokinetic profiles of pomalidomide were roughly similar between control mice and humanized-liver mice and that control and humanized-liver mice mediated pomalidomide 5-hydroxylation in vivo. Introducing one aromatic amino group into thalidomide resulted in less species differences in in vivo pharmacokinetics in control and humanized-liver mice.

Indexed as

Angiogenesis InhibitorsAnimalsCytochrome P-450 Enzyme SystemGlucuronidesHepatocytesHumansLiverMetabolomeMiceMicrosomes, LiverThalidomideAngiogenesis InhibitorsCytochrome P-450 Enzyme SystemGlucuronidespomalidomideThalidomidePBPK modelingpomalidomideTK-NOG mice

Identifiers

PMID27852146
PMCPMC5433912
OpenAlexW2551903959

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.